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ScienceDirectCurrent antiviral treatments can reduce HIV-associated
morbidity, prolong survival, and prevent HIV transmission.
Combination antiretroviral therapy (cART) containing preferably
three active drugs from two or more classes is required for
durable virologic suppression. Regimen selection is based on
virologic efficacy, potential for adverse effects, pill burden and
dosing frequency, drug–drug interaction potential, resistance
test results, comorbid conditions, social status, and cost. With
prolonged virologic suppression, improved clinical outcomes,
and longer survival, patients will be exposed to antiretroviral
agents for decades. Therefore, maximizing the safety and
tolerability of cART is a high priority. Emergence of resistance
and/or lack of tolerability in individual patients require
availability of a range of treatment options. Development of new
drugs is focused on improving safety (e.g. tenofovir
alafenamide) and/or resistance profile (e.g. doravirine) within
the existing drug classes, combination therapies with improved
adherence (e.g. single-tablet regimens), novel mechanisms of
action (e.g. attachment inhibitors, maturation inhibitors,
broadly neutralizing antibodies), and treatment simplification
with infrequent dosing (e.g. long-acting injectables). In parallel
with cART innovations, research and development efforts
focused on agents that target persistent HIV reservoirs may
lead to prolonged drug-free remission and HIV cure.
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Introduction
Since the approval of zidovudine (AZT) in 1987, over
25 antiretroviral agents in six mechanistic classes have
been approved to treat HIV infection (Figure 1). Combi-
nation antiretroviral therapy (cART) is the treatment
paradigm established in the late 1990s responsible for
the dramatic decline in AIDS deaths and is composed of
two nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) plus a third active drug from a different
class. Contemporary HIV treatment is highly effectiveCurrent Opinion in Virology 2016, 18:50–56 at suppressing plasma viremia, and significant progress
has been made toward regimen simplification through the
combination of three active drugs into single-tablet regi-
mens (STRs) (Figure 1) and optimization of drug profiles
that maximize long-term tolerability and safety. Lifelong,
chronic therapy without treatment interruption is the
standard of care, and the availability of multiple effective
drugs in several classes with differing resistance, safety,
and tolerability profiles provides choices after failure of
first-line treatment.
Herein, we review the current status of antiretroviral
therapy and guidelines for HIV-infected adults, as well
as prospects for further innovation in HIV treatment to
benefit patients and optimize their long-term health.
Goals of antiretroviral therapy
Eradication of HIV cannot be achieved with current
cART due to the pool of latently infected CD4 T cells
established early during acute infection. However, cART
can reduce HIV-associated morbidity, prolong survival,
and prevent HIV transmission [1–4]. Maximal and dura-
ble suppression of plasma viremia restores and preserves
immunologic function, delays or prevents the develop-
ment of drug-resistant mutations, and may also decrease
the immune activation and inflammation thought to con-
tribute to end-organ damage [5–7]. Suppressing plasma
viremia below detection limits is possible within weeks of
therapy and depends on adherence to an efficacious
regimen.
Morbidity and mortality in HIV-infected subjects is in-
creasingly driven by non-AIDS associated comorbidities
such as kidney, liver, and heart disease [8,9] (Linley L
et al., Abstract B08-1, 2007 National HIV Prevention
Conference, Atlanta, GA, December 2007). Even with
cART, aging patient populations with HIV-1 infection
experience more age-related comorbidities, such as dia-
betes, and cardiovascular, renal, and bone disease, which
manifest earlier than in HIV-uninfected peers [10]. With
prolonged virologic suppression, improved clinical out-
comes, and longer survival, patients may be exposed to
antiretroviral agents for decades [11]. Thus, maximizing
the safety and tolerability of cART regimens while main-
taining strong clinical efficacy is a high priority.
Guidelines and preferred regimens for first-
line therapy
Therapy used to be initiated based on decreasing CD4
cell count or clinical evidence of AIDS. More recently,
therapy is being initiated regardless of the CD4 cell
count, often immediately after a patient’s diagnosis, awww.sciencedirect.com
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tolerability and safety of contemporary cART drugs.
Antiretroviral regimens that contain at least two and
preferably three active drugs from two or more classes
are recommended for virologic suppression. Initial thera-
py generally consists of two NRTIs combined with a thirdwww.sciencedirect.com agent such as an integrase strand transfer inhibitor
(INSTI), a non-nucleoside reverse transcriptase inhibitor
(NNRTI), or a pharmacologically boosted protease inhib-
itor (PI). Global and regional guidelines have generally
consistent recommendations for first-line therapy
(Table 1); US and European guidelines have begun toCurrent Opinion in Virology 2016, 18:50–56
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Table 1
Recommended antiretroviral regimens for treatment-naı¨ve patients based on US DHHS guidelinesa
Regimen Components STR available Comment
NRTI NRTI Third agent
INSTI-based ABC 3TC DTG Yes (Triumeq) Only for patients who are HLA-B*5701 negative
TDF FTC DTG No
TDF FTC EVG/COBI Yes (Stribild) Only for patients with pre-antiretroviral therapy CrCl >70 mL/min
TAF FTC EVG/COBI Yes (Genvoya) Only for patients with pre-antiretroviral therapy CrCl 30 mL/min
TDF FTC RAL No
PI-based TDF FTC DRV/RTV No
3TC: lamivudine; ABC: abacavir; COBI: cobicistat; CrCl: creatinine clearance; DHHS: Department of Health and Human Services; DRV: darunavir;
DTG: dolutegravir; EVG: elvitegravir; FTC: emtricitabine; INSTI: integrase strand transfer inhibitor; NNRTI: non-nucleoside reverse transcriptase
inhibitor; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; PI: protease inhibitor; RAL: raltegravir; RTV: ritonavir; STR: single-tablet
regimen; TAF: tenofovir alafenamide; TDF: tenofovir disoproxil fumarate.
a Based on guidelines developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (https://aidsinfo.nih.gov/guidelines).emphasize INSTIs because of their high virologic efficacy
and excellent safety and tolerability profiles (e.g. Federally
approved HIV/AIDS medical practice guidelines; URL:
https://aidsinfo.nih.gov/guidelines). Efavirenz and ataza-
navir are no longer recommended because of long-recog-
nized tolerability and safety concerns and the availability of
better alternatives. Boosted PI-based treatment maintains
clinical value due to high genetic barrier to resistance in
patients at high risk for intermittent therapy because of
poor adherence.
Recommended NRTIs are tenofovir disoproxil fumarate
(TDF) or abacavir (ABC) used in combination with
emtricitabine (FTC) or lamivudine (3TC). Although
potent and generally well tolerated, TDF may cause
clinically significant renal toxicity and is associated with
greater reductions in bone mineral density than other
antiretrovirals [12–15]. The novel prodrug tenofovir ala-
fenamide (TAF) delivers approximately four-fold higher
intracellular levels of the active metabolite tenofovir
diphosphate at one-tenth of a dose relative to TDF,
allowing for much lower doses of TAF versus TDF
[16]. This lowers the plasma exposure of tenofovir by
90% relative to TDF, thereby reducing the risk of teno-
fovir-associated off-target effects. Another commonly
used NRTI, ABC, is a preferred NRTI when co-admin-
istered with 3TC and dolutegravir (DTG). ABC is also
associated with drug hypersensitivity, requires testing for
the HLA B*5701 allele, and may be linked to increased
rates of myocardial infarction [17–19]. Generally, selec-
tion of a regimen is centered on individual patients’ needs
based on virologic efficacy, potential adverse effects, pill
burden, dosing frequency, drug–drug interaction poten-
tial, resistance test results, comorbid conditions, and cost.
Treatment as prevention
Despite advances in the prevention and treatment of HIV
infection, the rate of new infections has remained rela-
tively unchanged over the past decade [20]. While sub-
stantial efforts to prevent HIV transmission have focusedCurrent Opinion in Virology 2016, 18:50–56 on individuals at risk of acquiring HIV, recent evidence
has highlighted the strong impact of cART on secondary
HIV transmission. In HIV-infected individuals, low plas-
ma HIV RNA is associated with decreased concentration
of virus in genital secretions [21–23], and HIV transmis-
sion risk is low when plasma viral loads are <400 copies/
mL [24]. In communities with high concentrations of
HIV-infected individuals, the use of cART is associated
with decreased community viral load and reduced rates of
new HIV diagnoses [25–27]. Recent clinical evidence
strongly supports the value of antiretroviral treatment
as prevention in sero-discordant couples; patients taking
cART had a 96% reduction in HIV transmission to their
uninfected partners [28].
Management of treatment-experienced
patients
While current antiretroviral regimens for treatment-naı¨ve
patients are highly effective and well tolerated, a regimen
change may be needed in individual patients because of a
lack of virologic suppression, drug adverse effects, or
avoidance of drug–drug interaction with other medica-
tions [29]. Therapeutic goals for experienced patients
remain the same as for naı¨ve patients: maintaining sup-
pression of virus replication while enabling immune
recovery and minimizing adverse drug effects. This
requires a highly individualized approach and frequent
monitoring as well as navigating the challenges of more
limited treatment options.
Treatment guidelines are important sources of informa-
tion for the management of treatment-experienced sub-
jects and include recommendations for drug resistance
testing, management of drug-related adverse effects, and
drug–drug interactions (Federally approved HIV/AIDS
medical practice guidelines; URL: https://aidsinfo.nih.
gov/guidelines).
If a regimen change is needed due to resistance, ideally the
new regimen should contain at least two or, preferably,www.sciencedirect.com
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requires careful review of patient treatment history and
resistance testing. Genotypic resistance testing is routinely
used as it is faster and cheaper than phenotypic testing and
can quickly detect resistance due to the presence of known
well-characterized mutations in the target viral gene(s).
Virologic failure on the currently recommended first-line
cART regimens due to emergence of drug resistance is
rare [30,31,32]. Resistance emergence could be more
frequent in NNRTI-containing first-line regimens com-
pared with those containing boosted PIs [33] or INSTI
[34]. Patients with multi-class resistance are undoubtedly
the most challenging group to treat because of limited
options. Depending on the nature and extent of the
resistance, the options may include drug classes not
generally recommended for initial therapy, such as entry
inhibitors maraviroc (CCR5 inhibitor) or enfuvirtide
(gp41 fusion inhibitor). Additional antiretroviral classes
such as Gag maturation inhibitors and gp120 entry inhi-
bitors are in clinical testing and could become valuable
options for individuals with multi-class resistance.
Another reason for changing an existing regimen can be
adverse effects and lack of tolerability. Examples include
central nervous system (CNS) toxicity associated with
NNRTIs, particularly efavirenz, and lipid changes or gas-
trointestinal toxicity associated with boosted PIs [35]. After
elimination of thymidine analogs from first-line therapy
and introduction of pre-screening for ABC hypersensitivi-
ty, NRTI-associated toxicity is relatively rare and includes
ABC-associated cardiovascular and lipid effects, and TDF-
associated renal and bone effects. TAF, the novel prodrug
of tenofovir, significantly reduces the renal and bone
effects associated with TDF [36], and multiple switch
studies from TDF to TAF are in progress (ClinicalTrials.-
gov Identifiers: NCT02345252 and NCT02345226). An
alternative strategy could be a switch to an NRTI-sparing
regimen. For example, an NRTI-sparing once-daily
DTG + rilpivirine (RPV) regimen is being tested in Phase
3 switch studies (NCT02429791 and NCT02422797).
New drugs in clinical development
Several new drugs from clinically validated classes are in
advanced stages of development. Doravirine (formerly MK-
1439) is a potent novel NNRTI with a favorable resistance
profile as it remains active against viruses with K103N and
Y181C mutations [37]. Doravirine reduced HIV viral load
by about 1.3 log in a 7-day monotherapy study [38]. Similar
efficacy to efavirenz was shown in a follow-up study, but
with fewer side effects, especially CNS-related, following
treatment in combination with TDF/FTC [39]. Cabote-
gravir (formerly GSK1265744) is an orally bioavailable
INSTI chemically related to DTG with potent activity
and a long half-life [40]. Oral cabotegravir has shown
antiretroviral efficacy in a short-term monotherapy trial
[41], and an injectable nanosuspension-based formulationwww.sciencedirect.com administered subcutaneously or intramuscularly once every
4–8 weeks resulted in sufficient systemic drug exposures
[42] and was effective as a long-acting therapy in combi-
nation with RPV (Margolis D et al., Abstract 31LB, CROI,
Boston, MA, February 2016). GS-9883 is another novel
unboosted INSTI currently being tested in treatment-
naı¨ve HIV-infected patients in combination with TAF
and FTC (NCT02607930 and NCT02607956).
Among the antiretrovirals with novel mechanisms, BMS-
663068 (fostemsavir) is an oral prodrug of HIV attachment
inhibitor BMS-626529 [43]. BMS-626529 inhibits HIV
entry into CD4 cells by binding to the gp120 envelope
protein and preventing a conformational change that is
normally required to bind HIV co-receptor [44]. In a
Phase 2b, randomized, active-controlled trial in treat-
ment-experienced subjects virologic response rates and
immunologic reconstitution were similar across the BMS-
663068 and ritonavir-boosted atazanavir (ATV/r) arms
through week 48 (Thompson M et al., Abstract 545,
CROI, Seattle, WA, February 2015).
Maturation inhibitors represent another novel class of
antiretrovirals that specifically interfere with processing
of the p24/p1 cleavage site in Gag polyprotein, a distinct
mechanism of virus maturation inhibition from that
exerted by HIV PIs. BMS-955176 is an oral once-daily
second-generation maturation inhibitor with improved
potency against HIV variants with Gag polymorphism
over the first-generation inhibitors (Protack Y et al., Ab-
stract, 15th European AIDS Conference, Barcelona,
Spain, October 2015). In a proof-of-concept monotherapy
study, 10-day dosing of BMS-955176 resulted in plasma
viral load reduction of up to 1.7 log10 copies/mL (Hwang
C et al., Abstract 114LB, CROI, Seattle, WA, February
2015). In combination with ATV +/ ritonavir (RTV),
BMS-955176 was well tolerated and showed clinical
efficacy (Hwang C et al., Abstract PS10/5, 15th European
AIDS Conference, Barcelona, Spain, October 2015).
GSK2838232 is another second-generation maturation
inhibitor active against HIV isolates resistant to bevirimat
(Jeffrey J et al., Abstract 538, CROI, Seattle, WA, Febru-
ary 2015). Its clinical development began by testing it
alone and in combination with RTV in healthy subjects
(NCT02289495).
Broadly neutralizing antibodies (bNAbs) targeting the
viral envelope have been tested in small proof-of-concept
Phase 1 monotherapy studies. Antibodies 3BNC117 and
VRC01 have shown HIV suppression in several subjects,
but resistance emergence and/or preexisting HIV variants
refractory to the treatment are among current concerns
[45,46]. In contrast to bNAbs, the antibody PRO140
targets CXCR5 co-receptor and provided sustained viro-
logic suppression in a Phase 2b study in HIV-infected
subjects who switched from their suppressive antiretro-
viral therapy to a subcutaneously self-administeredCurrent Opinion in Virology 2016, 18:50–56
54 Antiviral strategiesmonotherapy with PRO140 once weekly for >1 year
(Cytodyn press release; URL: http://www.cytodyn.com/
media/press-releases/detail/223/cytodyn-reports-full-
virologic-suppression-in-eleven-hiv).
Future directions of HIV treatment
In addition to durable efficacy, safety and tolerability will
continue to play an important role in the long-term
success of HIV therapies. In addition, further simplifica-
tion of antiretroviral regimens will likely be a focus of
future clinical development [47]. At least two 2-drug
STRs (DTG/RPV and 3TC/DTG) are being developed,
challenging the paradigm of two-NRTI backbone com-
bined with a third agent. 3TC/DTG combination has
shown promising results in a small proof-of-concept study
in treatment-naı¨ve patients after 24 weeks of treatment
(Figueroa MI et al., abstract LBPS4/1, 15th European
AIDS Conference, Barcelona, Spain, October 2015). Ad-
ditional once-daily NRTI-sparing regimens such as
DTG + cobicistat-boosted darunavir (DRV) are planned
to be tested (NCT02499978 and NCT02486133). While
encouraging results may be obtained from 24-week to 48-
week trials, it will be important to establish the longer-
term durability of viral suppression without resistance
emergence of the 2-drug regimens side-by-side with the
currently preferred 3-drug regimens.
Long-acting injectable formulations of drugs with estab-
lished oral efficacy such as cabotegravir and RPV will be
assessed in Phase 3 registrational trials and, if proven to
show long-term safety and efficacy, would provide addi-
tional options for simplified and potentially more conve-
nient maintenance therapy. However, long-term
sustainability and tolerability of monthly/bi-monthly in-
tramuscular injections needs to be established. Other
sustained-release drug delivery technologies may further
increase the convenience of antiretroviral therapy, but
these would likely require more potent drugs due to the
limited capacity of patches, implants and other currently
available drug delivery technologies.
Antiretroviral drugs with new mechanisms of action such
as the attachment and maturation inhibitors are in ad-
vanced stages of clinical testing and, if approved, would
broaden treatment options especially for individuals with
multi-class resistance needing salvage therapy. Hopeful-
ly, one or more of these new class agents will be suitable
for co-formulation with existing antiretrovirals to generate
STRs for second-line and third-line therapies.
These advancements in the development of new antire-
troviral therapies and treatment paradigms will be happen-
ing in parallel with the increased availability of generic
antiretrovirals. In the absence of an efficacious vaccine, the
effective and widespread use of antiretrovirals for treat-
ment and prevention is the key approach to curb the global
AIDS epidemics. Therefore, these innovations will beCurrent Opinion in Virology 2016, 18:50–56 essential to achieve the ambitious goals in global imple-
mentation of antiretroviral therapy. In 2014, UNAIDS set a
‘90–90–90’ target aiming to diagnose 90% of all people
infected with HIV, provide treatment for 90% of those
diagnosed, and achieve full viral suppression in 90% of
those on treatment by 2020 (UNAIDS; URL: http://www.
unaids.org/en/resources/documents/2014/90-90-90). This
translates into successfully treating >70% of all individuals
infected with HIV, representing almost 25 million people
worldwide.
In parallel with antiretroviral therapy innovations, re-
search and development efforts are expanding toward
new therapeutic approaches for targeting persistent
HIV reservoirs that may lead to prolonged drug-free
remission of the infection and potentially to HIV cure
[48,49]. These new directions are focused on latency-
reversing agents to activate the viral reservoirs, immu-
notherapies including innate immunity activators and
effector antibodies, gene therapies, and therapeutic vac-
cines to eliminate the persistent viral reservoirs or induce
effective immune control of HIV infection [48,49]. All
these efforts are in early stages of testing, and long-term
systematic research and commitment will be necessary to
assess their true therapeutic potential. Ultimately, these
technologies may lead to fundamental changes in the
HIV healthcare.
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